Stockreport

Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss [Yahoo! Finance]

Kymera Therapeutics, Inc.  (KYMR) 
PDF Regeneron (REGN)'s dupilumab serves a $20B market. Kymera dosed the first IRF5-directed therapy in human history and its oral drug matched Regeneron's injectable dupil [Read more]